# OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA

> **NCT01694758** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 733 (actual)

## Conditions studied

- Diabetes Mellitus, Non-Insulin-Dependent

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01694758
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 733 (ACTUAL)
- **Last updated:** 2014-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01694758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01694758, "OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01694758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*